Business Context and Reporting Period
Company: Harvard Bioscience, Inc. (HBIO)
Filing Type: Form 8-K (Current Report)
Date of Report: November 5, 2019
Reporting Period: The filing reports on events occurring on November 5, 2019, and references financial results for the three and nine months ended September 30, 2019.
Key Financial Metrics
This filing does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It references a press release (Exhibit 99.1) containing the financial results for the period ended September 30, 2019, but the text of the 8-K itself does not disclose these figures.
Material Changes
The primary material change reported is the entry into a Second Amendment to the Financing Agreement on November 5, 2019. Key modifications include:
- Leverage Ratio: Increased the maximum leverage ratio.
- EBITDA Adjustments: Increased the amount of restructuring and related costs excluded from consolidated EBITDA for certain periods.
- Coverage Ratio: Decreased the minimum fixed charge coverage ratio.
- Interest Rate: Modified the applicable interest rate margin to adjust based on the Company's leverage ratio.
- Prepayment Penalty: Extended the prepayment penalty periods.
Effective Dates:
- Covenant calculations: Effective for the period ended September 30, 2019.
- Minimum fixed charge coverage ratio change: Effective beginning the three months ended December 31, 2019.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release on November 5, 2019, announcing financial results and a conference call. The filing explicitly states that the information in Item 2.02 and the press release is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Risks and Contingencies: The filing does not detail specific new risks or contingencies beyond the modification of debt covenants. The amendment suggests the Company is managing its capital structure to accommodate leverage and restructuring costs.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net income, and cash flow figures for the three and nine months ended September 30, 2019.
- Examine Exhibit 10.1 (Second Amendment to Financing Agreement) for the exact terms of the new leverage ratios, interest rate margins, and prepayment penalties.
- Verify the impact of the increased restructuring cost exclusions on reported EBITDA.
- Confirm the Company's compliance with the new minimum fixed charge coverage ratio effective December 31, 2019.